SURF | Surface Oncology, Inc. | [NASD]
Index- P/E- EPS (ttm)-1.53 Insider Own0.70% Shs Outstand60.63M Perf Week-6.28%
Market Cap45.94M Forward P/E- EPS next Y-1.18 Insider Trans0.00% Shs Float60.18M Perf Month33.00%
Income-89.50M PEG- EPS next Q-0.34 Inst Own53.50% Short Float / Ratio1.50% / 4.28 Perf Quarter15.44%
Sales0.00M P/S- EPS this Y35.70% Inst Trans5.00% Short Interest0.90M Perf Half Y-15.79%
Book/sh1.25 P/B0.66 EPS next Y7.10% ROA-53.20% Target Price5.25 Perf Year-58.12%
Cash/sh1.82 P/C0.45 EPS next 5Y- ROE-87.80% 52W Range0.56 - 2.15 Perf YTD-2.44%
Dividend- P/FCF- EPS past 5Y7.90% ROI-52.00% 52W High-62.79% Beta1.66
Dividend %- Quick Ratio7.30 Sales past 5Y18.50% Gross Margin- 52W Low44.14% ATR0.07
Employees60 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)61.09 Volatility11.77% 9.51%
OptionableYes Debt/Eq0.34 EPS Q/Q-356.60% Profit Margin- Rel Volume0.69 Prev Close0.82
ShortableYes LT Debt/Eq0.30 Earnings- Payout- Avg Volume211.50K Price0.80
Recom1.60 SMA2017.99% SMA5021.76% SMA200-14.62% Volume52,694 Change-2.45%
Date Action Analyst Rating Change Price Target Change
May-18-21Initiated BTIG Research Buy $17
Sep-04-20Initiated H.C. Wainwright Buy $11
Aug-28-20Initiated Wedbush Outperform $12
Sep-19-18Initiated Robert W. Baird Outperform
May-14-18Initiated Goldman Neutral $17
May-14-18Initiated Evercore ISI Outperform $26
May-04-23 07:00AM
Apr-18-23 07:00AM
Mar-16-23 08:00AM
Mar-10-23 06:11AM
Mar-09-23 07:00AM
04:15PM Loading…
Feb-28-23 04:15PM
Feb-02-23 08:00AM
Jan-27-23 06:38AM
Jan-12-23 07:06AM
Jan-09-23 08:00AM
Jan-05-23 07:30AM
Nov-07-22 08:00AM
Nov-02-22 10:28AM
07:00AM Loading…
Oct-19-22 07:00AM
Sep-14-22 07:30AM
Sep-07-22 04:30PM
Aug-24-22 04:30PM
Aug-08-22 06:15AM
Aug-06-22 09:46AM
Aug-03-22 07:00AM
Aug-01-22 04:30PM
Jul-07-22 08:00AM
Jun-29-22 07:00AM
Jun-20-22 10:05AM
Jun-03-22 04:30PM
Jun-01-22 08:00AM
May-26-22 05:00PM
May-17-22 04:30PM
06:28AM Loading…
May-11-22 06:28AM
May-09-22 07:10AM
May-06-22 04:30PM
Apr-27-22 04:15PM
Apr-21-22 04:05PM
Apr-14-22 07:30AM
Apr-11-22 09:47AM
Apr-08-22 04:01PM
Apr-01-22 04:43PM
Mar-31-22 07:30AM
Mar-15-22 07:30AM
Mar-02-22 08:42AM
Mar-01-22 03:00PM
Feb-28-22 04:30PM
Feb-24-22 07:55AM
Feb-22-22 08:05AM
Feb-10-22 07:00AM
Jan-10-22 01:49PM
Dec-15-21 07:05AM
Dec-06-21 09:30AM
Dec-03-21 07:00AM
Dec-02-21 07:00AM
Dec-01-21 07:00AM
Nov-29-21 06:44AM
Nov-26-21 06:57AM
Nov-09-21 08:10AM
Nov-08-21 03:44PM
Nov-04-21 07:10AM
Nov-02-21 07:00AM
Oct-12-21 11:21AM
Oct-04-21 10:56AM
Sep-20-21 05:44PM
Sep-13-21 09:02AM
Aug-23-21 12:03PM
Aug-05-21 07:10AM
Jul-08-21 07:00AM
Jun-04-21 10:17AM
May-28-21 06:20AM
May-24-21 08:53AM
May-18-21 08:48AM
May-16-21 06:20AM
May-05-21 06:45AM
Apr-28-21 04:05PM
Apr-27-21 07:00AM
Apr-19-21 07:00AM
Apr-09-21 07:53AM
Apr-08-21 07:32AM
Mar-31-21 11:12AM
Mar-30-21 06:11PM
Mar-23-21 11:47PM
Mar-18-21 08:00AM
Mar-17-21 08:01AM
Mar-10-21 04:35PM
Mar-09-21 08:25AM
Mar-05-21 08:48AM
Mar-02-21 12:30PM
Feb-24-21 07:00AM
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSS ROBERT W.Chief Executive OfficerAug 03Sale1.7210,59418,22299,906Aug 05 08:00 PM
FEES JESSICAChief Financial OfficerAug 03Sale1.725,98010,286111,349Aug 05 08:00 PM
RATH HENRY C.Chief Business OfficerAug 03Sale1.725,6769,76332,324Aug 05 08:01 PM
ONEILL ALISONChief Medical OfficerAug 03Sale1.724,4637,67663,728Aug 05 08:01 PM
Palombella Vito J.Chief Scientific OfficerAug 03Sale1.724,4637,67687,212Aug 05 08:00 PM